STALICLA
Joaquim Aguirre-Plans is a Computational Systems Biologist at STALICLA since April 2023, previously serving as a Postdoctoral Research Associate in the Center for Complex Network Research at Northeastern University from July 2021 to March 2023. Joaquim completed a PhD in Structural Bioinformatics at Universitat Pompeu Fabra from September 2017 to April 2021, under the supervision of Drs. Baldo Oliva and Narcis Fernandez-Fuentes. Joaquim's earlier experience includes a master internship in Bioinformatics at HelmholtzZentrum München, an MSc research role at the Structural Bioinformatics Group at Universitat Pompeu Fabra, and undergraduate research positions at IRTA - CReSA and Universitat Autònoma de Barcelona. Joaquim holds a Master of Science in Bioinformatics for Health Sciences from Universitat Pompeu Fabra and a Bachelor of Science in Biotechnology from Universitat Autònoma de Barcelona.
This person is not in any offices
STALICLA
STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terriblebiomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value.Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb.STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.